Lupin is launching generic version of sleep disorder Nuvigil tablets in the US market. The brand has an annual market size of $515 million and Lupin is the third company to launch the generic version in the US.
On Tuesday Lupin announced it had received the US Food and Drug Administration department's final approval for the product and is launching the product shortly. The product was filed from the company's Goa plant which recently received clearance from the US drug regulator.
US business contributes over 40 per cent to the company revenue. In the first half, the business grew to 78 per cent to Rs 4,186 crore on a year on year basis. The results include the contribution of drug firm Gavis which the company acquired earlier this year.